2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145919
    hGPR91 antagonist 3 1314796-31-0 98.82%
    hGPR91 antagonist 3 (Compound 5g) is a potent and orally active GPR91 antagonist with IC50s of 35 nM and 135 nM, for human GPR91 and rat GPR91, respectively.
    hGPR91 antagonist 3
  • HY-147292
    Nelutroctiv 2299177-09-4 99.57%
    Nelutroctiv (CK-136) is an orally active and selective cardiac troponin activator. Nelutroctiv activates cardiac sarcomeres by enhancing the sensitivity of troponin to calcium ions and promoting the interaction between actin and myosin. Nelutroctiv enhances cardiac contractility. Nelutroctiv can be used in the researches for cardiovascular diseases with impaired cardiac contractile function.
    Nelutroctiv
  • HY-15284A
    Prasugrel hydrochloride 389574-19-0 98.49%
    Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
    Prasugrel hydrochloride
  • HY-153182
    GBT1118 1628799-51-8 99.37%
    GBT1118 is a potent and orally active allosteric modifier of hemoglobin oxygen affinity. GBT1118 increases tolerance to severe hypoxia.
    GBT1118
  • HY-B0757A
    (±)-α-Tocopherol nicotinate 51898-34-1 99.80%
    (±)-α-Tocopherol nicotinate, vitamin E - nicotinate, is an orally active fat-soluble antioxidant that prevents lipid peroxidation in cell membranes. (±)-α-Tocopherol nicotinate is hydrolysed in the blood to α -tocopherol and niacin and may be used in studies of related vascular diseases.
    (±)-α-Tocopherol nicotinate
  • HY-P1858A
    Urocortin III, mouse TFA
    Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2. Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics.
    Urocortin III, mouse TFA
  • HY-P3460A
    TDSRCVIGLYHPPLQVY TFA 99.95%
    TDSRCVIGLYHPPLQVY TFA is a disordered control peptide. TDSRCVIGLYHPPLQVY TFA is a peptide containing the same amino acids as LP17 (HY-P3400) but in a different sequence order.
    TDSRCVIGLYHPPLQVY TFA
  • HY-106844A
    (+)-EMD 57033 147527-31-9 99.72%
    (+)-EMD 57033 is a cardiac troponin C (cTnC) activator, is a dominant Ca2+ sensitizer. (+)-EMD 57033 binds the cardiac/slow skeletal troponin C isoform and exerts myocardial contractile promotion function.
    (+)-EMD 57033
  • HY-N0666S3
    L-Aspartic acid-15N 3715-16-0 ≥98.0%
    L-Aspartic acid-15N is the 15N-labeled L-Aspartic acid. L-Aspartic acid is is an amino acid, shown to be a suitable proagent for colon-specific agent deliverly.
    L-Aspartic acid-15N
  • HY-N0830S7
    Palmitic acid-d4 75736-49-1 ≥98.0%
    Palmitic acid-d4 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-d4
  • HY-W416250
    p-Cresol glucuronide 17680-99-8
    p-Cresol glucuronide, a metabolite of p-cresol, is a prototype protein-bound uremic toxin. p-Cresol glucuronide is associated with chronic kidney disease (CKD).
    p-Cresol glucuronide
  • HY-113313S1
    Aldosterone-d7 ≥99.0%
    Aldosterone-d7 is the deuterium labeled Aldosterone. Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by the zona glomerulosa (ZG) of the adrenal cortex. Aldosterone activity is dependent by the binding and activation of the cytoplasmic/nuclear mineralocorticoid receptor (MR) at cellular level.
    Aldosterone-d7
  • HY-B0428
    Ozagrel 82571-53-7 99.74%
    Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.
    Ozagrel
  • HY-B1469
    Isosorbide 652-67-5 ≥98.0%
    Isosorbide (D-Isosorbide), an orally active vasodilating agent that can be used for the research of heart failure and angina (chest pain). Isosorbide is also an oral hyperosmotic diuretic.
    Isosorbide
  • HY-N8354
    6',7'-Dihydroxybergamottin 145414-76-2 ≥99.0%
    6',7'-Dihydroxybergamottin (6′,7′-DHB), a furanocoumarin, is a potent CYP3A4 inhibitor.
    6',7'-Dihydroxybergamottin
  • HY-106591A
    4-Vinylcyclohexene dioxide 106-87-6 ≥98.0%
    4-Vinylcyclohexene dioxide is a metabolite of 4-vinylcyclohexene that can specifically destroy oocytes in primordial and primary follicles of rats and mice. 4-Vinylcyclohexene dioxide induces apoptosis in rat cells is associated with activation of a caspase-mediated cascade.
    4-Vinylcyclohexene dioxide
  • HY-100408
    GNF-6231 1243245-18-2 99.63%
    GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction.
    GNF-6231
  • HY-14994
    SCH79797 dihydrochloride 1216720-69-2 ≥99.0%
    SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes.
    SCH79797 dihydrochloride
  • HY-109059
    Fulacimstat 1488354-15-9 99.92%
    Fulacimstat is an orally available chymase inhibitor, with IC50s of 4, 3 nM for human and hamster chymase enzyme, respectively.
    Fulacimstat
  • HY-B0185B
    Lidocaine hydrochloride hydrate 6108-05-0 99.90%
    Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia.
    Lidocaine hydrochloride hydrate
Cat. No. Product Name / Synonyms Application Reactivity